12:00 AM
Mar 19, 2012
 |  BC Week In Review  |  Company News  |  Other News

Onyx, Bayer, Natco cancer, generics news

The Indian Patent Office granted Natco a compulsory license in India to manufacture and market a generic version of kidney and liver cancer drug Nexavar sorafenib. According to the order, Natco can sell the product at a price not exceeding Rs8,880 ($177) for a month's supply of 120 tablets. Bayer markets...

Read the full 244 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >